Table 2.

HPV16 and HPV18 antibody levels at visit 48 months

HPV16
Vaccine dosenGMTs (95% CI) EU/mLGMT ratio (95% CI) (Alternate dose/3 dose)GMT ratio (95% CI) (Alternate dose/NI)n (%) above the lowest 3-dose levels at 48 monthsa
178137.49 (106.16–178.07)0.18 (0.14–0.24)9.36 (6.26–13.81)42 (53.85)
2 (0/1)140352.99 (302.03–412.55)0.47 (0.38–0.58)24.03 (17.78–32.52)123 (87.86)
2 (0/6)52519.99 (422.02–640.70)0.69 (0.53–0.89)35.40 (22.84–54.16)52 (100)
3120748.25 (647.63–864.49)50.94 (37.48–69.15)120 (100)
Natural infection11314.69 (11.12–19.40)0.0212 (10.62)
HPV18
Vaccine dosenGMTs (95% CI) EU/mLGMT ratio (Alternate dose/3 dose)GMT ratio (Alternate dose/NI)n (%) above the lowest 3-dose levels at 48 monthsa
17870.21 (54.37–90.67)0.21 (0.16–0.28)4.79 (3.37–6.86)63 (80.77)
2 (0/1)140206.75 (174.31–245.24)0.62 (0.49–0.78)14.10 (10.70–18.84)136 (97.14)
2 (0/6)52304.97 (237.76–391.18)0.91 (0.68–1.22)20.80 (14.15–30.86)52 (100)
3120334.55 (285.31–392.30)22.82 (17.23–30.37)119 (99.17)
Natural infection11314.66 (11.53–18.63)0.0431 (27.43)
  • aCalculated percentage of the participants that had values above 105 or 28 which are the lowest HPV16 and HPV18 level, respectively, at 48 month in CVT in the 3 doses group for whom vaccine efficacy has been observed.